ADAP News and Press, Adaptimmune Therapeutics plc From 02/21/24

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 21, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the fourth quarter...

2024-02-02 12:49:37 ET Summary Adaptimmune's BLA for their T-cell therapy in soft tissue sarcomas has been accepted for review by the FDA. The company's lead candidate, Afami-cel, has shown promising results in synovial sarcoma, with a PDUFA date set for August 4, 2024. Adapti...

2024-01-31 18:30:01 ET More on Adaptimmune Adaptimmune Therapeutics plc (ADAP) Q3 2023 Earnings Call Transcript Adaptimmune projects sarcoma franchise to deliver US peak year sales up to $400M Seeking Alpha’s Quant Rating on Adaptimmune Historical earn...

If approved, afami-cel will be the first engineered T-cell therapy for solid tumors and the first effective treatment option for synovial sarcoma in more than a decade Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 31, 2024) - Adaptimmune Therapeutics plc (NA...

2024-01-04 07:59:51 ET More on Adaptimmune Seeking Alpha’s Quant Rating on Adaptimmune Historical earnings data for Adaptimmune Financial information for Adaptimmune For further details see: Adaptimmune projects sarcoma franchise to deliver US peak...

Sarcoma franchise of afami-cel and lete-cel leverages same development and commercial footprint with US peak year sales projected to be up to $400 million BLA submitted in 2023 for afami-cel; projected acceptance by US FDA in Q1 2024 Company preparing for US launch of afami-cel in 2H 2024 upo...

First BLA for an engineered T-cell therapy for solid tumors submitted to U.S. Food and Drug Administration Afami-cel data demonstrate better outcomes for people with synovial sarcoma compared to historical control data; pivotal trial has met primary endpoint for efficacy Philadelphia, Pennsylva...

Interim analysis of pivotal IGNYTE-ESO trial demonstrates 40% response rate in people with synovial sarcoma or myxoid/ round cell liposarcoma Company will lay out plans for its cell therapy sarcoma franchise including afami-cel and lete-cel in January 2024 Philadelphia, Pennsylvania. and Oxfo...

Adaptimmune Therapeutics plc (ADAP) is expected to report $-0.2 for Q3 2023

2023-11-08 11:45:19 ET Adaptimmune Therapeutics plc (ADAP) Q3 2023 Earnings Conference Call November 8, 2023 8:00 AM ET Company Participants Juli Miller – Investor Relations Adrian Rawcliffe – Chief Executive Officer Dennis Williams – Senior ...